Danaher Corporation DHR

Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, today announced that it received two honors at the 2026 Octane High Tech Awards, winning Deal of the Year and Best Technology Company Leadership Team.

Gilead Sciences, Inc. (NASDAQ:GILD) and Danaher Corporation (NYSE:DHR) are both showing signs of stronger growth, but they are getting there in very different ways. Gilead already has momentum, which is supported by its HIV business that is expanding at a double-digit rate, with newer products contributing more and resulting in management raising its sales outlook. […]

Leica Biosystems, a Danaher company (the "Company") and a global leader in digital and anatomic pathology solutions advancing precision cancer diagnostics, announced today that the Company has completed its acquisition of privately held StatLab Medical Products ("StatLab"), a leading provider of pre-analytical consumables and equipment, from Linden Capital Partners and Audax Private Equity. For patients and their care teams, precision cancer diagnostics can provide critical information about the

Opportunities center on automated, standardized TDM kits integrated with AI dosing tools for antimicrobial stewardship, transplant care and precision medicine, especially in Asia-Pacific.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "TDM Reagent Kit Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global TDM Reagent Kit Market, projected to reach USD 2.87 billion in 2026 and grow at a CAGR of 15.84% to USD 6.96 billion

Danaher has delivered a 17.4% gain over the past year, which puts a spotlight on one core issue for anyone looking at the stock today: whether the current share price can be explained by the cash flows the business is expected to generate. The 17.4% 1 year return means recent buyers have seen a clear payoff, which raises the question of how much future cash generation is already reflected in the valuation. Recent reports on areas such as label free detection and single use bioreactors...

ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer. "Sidharth has a proven track record of building and scaling corporate development functions inside some of the largest healthcare companies in the

Biologics, stricter purity rules and flexible manufacturing are driving demand for single-use, automated and continuous filtration, advanced membranes and sustainable systems.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Pharmaceutical Filtration - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Pharmaceutical Filtration was estimated at US$8.0 Billion in 2025 and is projected to reach US$23.4 Billion by 2032, growing at a CAGR of 16.7% f

Bioreactors Market Gains Momentum as Single-Use Systems, Automation and Advanced Therapies Reshape BiomanufacturingDublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Bioreactors Market Opportunity, Growth Drivers, Industry Trend Analysis and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Bioreactors Market to Reach USD 38.9 Billion by 2035 as Advanced Biomanufacturing Expands The global bioreactors market was valued at USD 13.8 billion in 2025 and is projected to reach

The Dow Jones index fell on the stock market today after President Trump threatened Iran. Other major indexes rose. Apple was among stocks trading near buy points.

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2026 on Wednesday, October 21, 2026 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations.

AI-enabled, microfluidic label-free detection is expanding in drug discovery, early diagnostics, food safety and environmental testing, driven by efficient, non-invasive, sustainable workflows.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Label-Free Detection - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Label-Free Detection was valued at US$553 Million in 2024 and is projected to reach US$847 Million by 2030, growing at a CAGR of 7.4

Demand is rising for single-use, automated and real-time aseptic sampling as biopharma and food producers prioritize contamination control, continuous manufacturing and compliance.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Aseptic Sampling - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Aseptic Sampling was estimated at US$867.4 Million in 2025 and is projected to reach US$1.3 Billion by 2032, growing at a CAGR of 6.3% from 2025 to 2

High-content screening is advancing drug discovery and personalized medicine, driven by 3D models, advanced imaging and automated analytics, with opportunities in cancer research and organoids.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "High Content Screening (HCS) - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for High Content Screening (HCS) was valued at US$1.3 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing

Healthcare services and products company Cardinal Health (NYSE:CAH)’s shares are up by more than 10% year-to-date but are down by more than 8% since early September. Cramer discussed the firm’s share price performance in his morning appearance on September 15th and wondered whether the weakness was due to a rotation into AI stocks rather than […]

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Danaher (DHR) has reaffirmed its shareholder payout, with the Board approving a regular quarterly cash dividend of $0.40 per share, payable on October 30, 2026, to holders of record on September 30. The reaffirmed dividend lands at a time when Danaher’s short-term momentum has picked up. The 90-day share price return is 17.78% and the 1-year total shareholder return is 10.73%, even though the 5-year total shareholder return is down 25.46%. Compare Danaher’s mix of dividend income and recent...